Although oxaliplatin shifts Bcl-x splicing in all cancer cell lines tested so far (Shkreta et al., 2008), as PKC signaling does not contribute to Bcl-x splicing control in the cancer cell lines that we have tested (Revil et al., 2007), it will be worth exploring whether the signaling network that controls SRSF10 phosphorylation also operates in cancer cell lines. This evidence concerns the gene PRRT2 and cancer.